E. Rowinsky

发表

A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.

A. Tolcher, G. Weiss, D. V. Von Hoff, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.

G. Weiss, E. Raymond, D. V. Von Hoff, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.

A. Tolcher, T. Whiteside, J. Stephenson, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.

M. Hidalgo, L. Siu, J. Irish, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma MMPs as surrogates of BAY 12-9566.

S. Zucker, S. Eckhardt, E. Rowinsky, 2000, Journal of Clinical Oncology.

Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

E. Rowinsky, WP Mcguire, NB Rosenhein, 1990, Annals of internal medicine.

Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.

G. Wilding, H. Hurwitz, D. Cohen, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

A. Tolcher, A. Patnaik, M. Mita, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A Risk-Benefit Assessment of Irinotecan in Solid Tumours

L. Siu, E. Rowinsky, E. Rowinsky, 1998, Drug safety.

Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.

Cesario Z. Cerna, D. V. Von Hoff, L. Siu, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.

D. V. Von Hoff, T. Petit, P. Ravdin, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.

D. V. Von Hoff, A. Patnaik, L. Hammond, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: Preliminary phase 1 results

C. Takimoto, J. Tabernero, E. Martinelli, 2005 .

A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors

A. Tolcher, L. Weiner, A. Patnaik, 2004 .

Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor

M. Ratain, A. Tolcher, M. Mita, 2005 .

Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: Results of a phase I study

A. Tolcher, C. Takimoto, M. Mita, 2005 .

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

L. Grochow, D. Ettinger, C. Hendricks, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.

E. Winer, D. Ettinger, D. Noe, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.

E K Rowinsky, L. Grochow, D. Ettinger, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequences of taxol and cisplatin: a phase I and pharmacologic study.

E K Rowinsky, L. Grochow, D. Ettinger, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot, pharmacokinetic (PK), and pharmacodynamic (PD) study to determine the feasibility of intrapatient dose escalation to tolerable rash and the activity of maximal doses of erlotinib (E) in previously treated patients with advanced non-small cell lung cancer (NSCLC)

K. Papadopoulos, M. Mita, G. Schwartz, 2005 .

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.

L. Grochow, D. Ettinger, R. Donehower, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.